SN BioScience and Boryung Announce the Licensing Agreement on Generic Version of Abraxane
First Generic of Abraxane in Korea, World 4th Commercial Scale-Up Global tech-transfer expected to US, Japan, and Europe SEONGNAM, South Korea, Jan. 26, 2023 /PRNewswire/ -- SN BioScience (CEO Park Young-hwan) and Boryeong (CEO Jang Doo-hyun) signed a domestic manufacturing technology transfer and co-development contract for the albumin nanoparticle anticancer...
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit Further developments are planned to conduct with a licensing/collaboration partner BOSTON and SEOUL, Korea, Jan. 26, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com)...
HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders
CAMBRIDGE, Mass., Jan. 26, 2023 /PRNewswire/ -- HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced that it completed seed financing to advance its leading programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS), with the lead candidate currently in IND-enabling stage. HBMAT was founded on the...
Daewoong Pharmaceutical submitted NDA for its global new drug Fexuclue in 11 countries, only 1 year after approval in Korea
"Expected to change GERD drug market landscape" Application for product approval of Fexuclue, a new drug for gastroesophageal reflux disease (GERD), has been completely submitted to Colombia, Vietnam, and Saudi Arabia NDA submissions in 11 countries completed in the shortest time among K-pharma new drugs... accelerating expansions into...
GenKOre Announces Collaboration with a US-based Company on In vivo Gene-editing Therapy
SEOUL, South Korea, Jan. 26, 2023 /PRNewswire/ -- GenKOre, Inc., a Korea-based biotech company with hypercompact CRISPR-Cas tools, announced that it has entered into a strategic research collaboration with a US-based biopharma company for the development of in vivo gene editing therapies. This collaboration will utilize GenKOre's proprietary CRISPR-Cas platform, TaRGET (Tiny nuclease, augment RNA-based Genome Editing Technology). The TaRGET platform is distinct from the most popular genome editing technology, CRISPR-Cas9, in that the whole editing module can be delivered with a single AAV vector. Based on their TaRGET...
ReLive Biotechnologies, Ltd. Completes Asset Purchase of Co.Don AG and Series A Financing Led By SHC, Furthering its Ambition to Become the Global Leader in Regenerative Therapies
NANJING, China, Jan. 26, 2023 /PRNewswire/ -- As the tissue engineering and regenerative treatment industry has shown tremendous potential in clinical practices in recent years worldwide, China's blue ocean market welcomes the first wave of acquisitions. ReLive Biotechnologies, Ltd. ("ReLive" or "Company", a leading industry player, announces it has completed the acquisition of all operating assets of Germany-listed...
MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study
GENEVA, Jan. 26, 2023 /PRNewswire/ -- The first US patient has been enrolled at MedStar Washington Hospital Center in the SELUTION4ISR study evaluating SELUTION SLR™ to support FDA approval. This milestone follows Investigational Device Exemption (IDE) approval in the US in October 2022. SELUTION SLR is the first sustained limus release coronary drug-eluting...
Correction – Health in Transportation Releases New Smartphone Face-Scanning Application Aimed at Uncovering Potentially Serious Health Concerns in Professional Drivers
Correction Notice Please note the following corrections to the Press Release issued Jan 17, 2023: The CDL Health Scanner is a product of Health in Transportation. NuraLogix does not hold any liability for any applications distributed under the Health in Transportation name. NuraLogix technology, service and products do not uncover, nor identify life-threatening health conditions. NuraLogix technology, service...
Breg Partners with Correal International to Provide Orthopedic Products to Physicians & Patients in China
CARLSBAD, Calif., Jan. 26, 2023 /PRNewswire/ -- Breg, Inc., a leading orthopedic bracing and billing services company, announced today that it has partnered with medical device supplier Coreal International to bring its broad portfolio of bracing and cold therapy products to Chinese physicians and their patients. "China represents an exciting market...
CO.DON finally saved – investor has taken over the business operations of the Leipzig-based biopharmacy company with an additional location in Teltow, Brandenburg.
CO.DON continues business operations as a GmbH (limited liability company) LEIPZIG and TELTOW, GERMANY, Jan. 26, 2023 /PRNewswire/ -- With effect from 20.01.2023, CO.DON's business activities will be continued in the legal form of a GmbH (limited liability company) following a transferring reorganisation. The asset deal with Rejuvenate GmbH, a company of the American-Chinese ReLive Group, concluded in October...
